New pill NP-101 tested in patients with Hard-to-Treat cancers

NCT ID NCT06563375

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing an oral drug called NP-101 in 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and side effects, with a secondary look at whether the drug can shrink tumors. Because it is a Phase 1 study, it is too early to know if NP-101 will work, but it may point toward a new treatment option for people with few alternatives.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NP-101 (taken by mouth)
What this could lead to: If safe and effective, NP-101 could become a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 35 participants, focused on safety. It is too small to prove effectiveness, and many early-stage drugs fail to show benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.